

KSQ-001: A CRISPR/Cas9-Engineered Tumor Infiltrating Lymphocyte (eTIL™) Therapy for Solid Tumors

Nick Colletti, Rob LaMothe, Caroline Bullock, Sean Arlauckas, Pete Mitchell, Anja F. Hohmann, Hugh Gannon, Alejandra Falla, Noah Tubo, Aria Pearlman-Morales, Christopher Wrocklage, Nafeeza Hafeez, Paula Grasberger, Suphinya Sathitloetsakun, Isabelle Le Mercier, Jason J. Merkin, Anna Provaznik, Tracy E. Garrett, Sean Keegan, Sol Shenker, Charlotte Franco, Andrew Olaharski, Frank Stegmeier, Gregory V. Kryukov, Louise Cadzow, Mike Schlabach, Micah J. Benson



KSQ Therapeutics, Cambridge, MA

Abstract

Adoptive cell therapy (ACT) with ex vivo expanded tumor infiltrating lymphocytes (TIL) offers a potentially transformative therapy for treatment refractory solid tumors. However, the immunosuppressive tumor microenvironment (TME) limits the effectiveness of TIL therapy. To systematically identify targets that have the potential to improve T-cell function in the TME, we conducted two CRISPR/Cas9 functional genomic screens of immune cells using our proprietary CRISPRomics® platform. The first screen employed primary mouse T cells and assessed in vivo T cell infiltration into tumors by measuring sgRNA guide enrichment. Notably, this genome-wide screen identified clinically active targets, such as PD-1, and identified multiple targets, including Cell Therapy-1 (CT-1). The potential of inactivating 'CT-1' to enable ACT in the clinic was demonstrated by our finding that CT-1 edited TCR-Tg mouse T cells are 10x more potent than control-edited T cells in an in vivo syngeneic solid tumor model. A second CRISPR/Cas9 functional genomic screen employed human TIL and assessed the impact of gene inactivation on human TIL expansion under standard manufacturing conditions. This screen also identified CT-1 as a top target. We therefore prioritized the development of KSQ-001, an engineered TIL (eTIL™) therapy, created via CRISPR/Cas9-mediated editing of CT-1. Potent and selective sgRNAs targeting CT-1 were identified and characterized, and manufacturing methods to engineer human TIL with high efficiency have been developed. KSQ-001 manufactured from human melanoma TIL possess an in vitro profile consistent with increased anti-tumor potency in comparison to TIL, including heightened production of IFN γ and TNF α . Together, these data demonstrate that our CRISPRomics® platform enables comprehensive target identification and validation of compelling new targets for the development of robust eTIL™ therapies and support the clinical evaluation of KSQ-001 as a next generation-adoptive cell therapy in treatment-refractory solid tumors.

Methods

In vivo T-cell screen: CD8 T cells were isolated from OT1 x Cas9 Transgenic mice, transduced with an sgRNA library and adoptively transferred into B16-OVA tumor bearing mice. After in vivo expansion, tumors were collected, gDNA was isolated and sgRNA accumulation was evaluated by NGS.


In vitro TIL screen: Human melanoma TILs were expanded by culture with human recombinant IL-2. After expansion, TIL were transduced with an sgRNA library and subsequently transfected with mRNA encoding Cas9. Engineered TILs were expanded in a standard Rapid Expansion Phase (REP) containing irradiated PBMCs, anti-CD3, and IL-2 for 14 days. After expansion gDNA was isolated and sgRNA accumulation was determined by NGS.

In vivo Target validation: B16-Ova melanoma cancer cells were injected s.c. into C57BL/6J mice. Mice were randomized for tumor volume (approx. mean 100mm³) and either control or CT-1 edited OT1 T cells were injected i.v. Tumor volume and body weights were measured twice a week. Relative potency of mKSQ-001 vs control edited T cells was evaluated in the B16-Ova model at cell doses ranging from 0.41 to 41x10⁶ cells. Day 21 post cell transfer, blood was collected from the highest dose groups and OT-1 T cells measured for expansion (Fig 2).


Manufacture & characterization of human KSQ-001: For pre-REP, single cell tumor digests from Stage III treatment-naïve melanoma patients were cultured in 6000U IL-2 for 20-30 days, until ~50x10⁶ TIL per donor were obtained. CRISPR/Cas9 RNPs targeting either the CT-1 gene or OR1A1 gene (sgControl) were electroporated into TIL, with edited TIL expanded in G-REX flasks with irradiated PBMCs, 30ng/ml OKT3 and 6000U IL-2 (REP). KSQ-001 and sgControl-edited TIL viability were assessed by AOPI stain from Nexcelom, with MART-1 tetramers from MBL.

Figure 1: A genome-wide CRISPR/Cas9 in vivo T-cell screen identifies CT-1 as a top target

Experimental schematic of OT1 / B16-Ova in vivo T cell CRISPR screen




Genome-Scale in vivo Screen Identifies Novel T cell Targets



- Genome-wide *in vivo* screen IDs targets driving T cell enrichment in the tumor
- PD-1 serves as a positive control, the gene code-named Cell Therapy-1 (CT-1) demonstrates activity greater than PD-1
- Screen passes multiple QC checks, including recovery of >90% sgRNAs in library, depletion of T cell essential genes (Zap70, Il2rg), and expression of hits in T cells



Figure 2: Murine KSQ-001 is 10x more potent and accumulates 5x greater than Control T cells



- CT-1 edited murine KSQ-001 (mKSQ-001) possess 10x potency increase in comparison to control edited T cells in the B16-Ova model
- At 21 days post adoptive transfer, mKSQ-001 are found at a 5x higher frequency in the peripheral blood compared to sgControl-edited T cells


Figure 3: A Human TIL Manufacturability CRISPR Screen Identifies CT-1 as a Top Target

TIL CRISPR screen schematic:




- A pooled CRISPR screen on the TIL manufacturing REP identified the CT-1 gene as the top target enhancing TIL expansion
- T cell relevant dropouts, including STAT5A, were observed in the screen, demonstrating quality

Figure 4: Robust Manufacture of KSQ-001 from Human Melanoma TIL




- KSQ-001 was manufactured from n=5 Stage III-IV human melanoma donors, with sgControl-edit TIL as comparators
- Robust editing of the CT-1 gene was observed across donors for KSQ-001 by amplicon sequencing (Figure 4A)
- KSQ-001 displays similar expansion, viability and anti-CD3 mediated AICD levels in comparison to sgControl-edited TIL following the REP (Figures 4B-D)

Figure 5: The Cellular Composition of KSQ-001 Matches Control TIL



- KSQ-001 possesses CD4⁺ and CD8⁺ T cell populations at frequencies similar to sgControl TIL (Figure 5A)
- KSQ-001 is composed primarily of CCR7⁺CD45RO⁺ T effector memory T cells, with a low frequency of T central memory (CCR7⁺CD45RO⁺) cells (Figure 5B)


Figure 6: KSQ-001 Produces Increased Cytokines & Maintains Anti-Tumor Specificity



- KSQ-001 produced higher amounts of secreted IFN γ and TNF α following anti-CD3 stimulation in comparison to sgControl edited TIL (Figure 6A; combined data from 5 donors)

- An HLA-A2⁺ donor contained specificity for the Mart-1 tumor antigen following pre-REP (Figure 6B). Following the REP, KSQ-001 from this donor retained Mart-1 specificity similar to sgControl-edited TIL. HLA-A1⁺ donor shown as a control

Figure 7: KSQ-001 Displays Heightened Expression of Transcripts Associated with Anti-Tumor Function



- mRNA from n=5 KSQ-001 and sgControl samples were run on the Nanostring CAR-T Characterization Panel

- KSQ-001 exhibits increased expression of T cell activation markers (TIM3, LAG3, CD200); cytokines (CCL3, IFN γ , TNF α , IL-13, CCL23) cytokine signaling (IL-2RB, IL12RB2, IRF7), cytolytic proteins (GrzB, Prf1) and T cell signaling pathway components (Jun) in comparison to sgControl TIL

Conclusions

- CRISPR screens identified CT-1 as a top solid tumor ACT target
- Inactivation of CT-1 in mKSQ-001 increases anti-tumor potency by 10x versus unedited T cells
- Human KSQ-001 is an eTIL™ with comparable manufacturability, viability and cellularity profiles as unedited TIL
- Human KSQ-001 demonstrates an invitro functional profile consistent with enhanced anti-tumor properties